Live Feeds
● TRACKER Updated 9d ago · 41 sources tracked

Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal

Novartis has secured exclusive worldwide rights to ABO2203, an experimental mRNA-encoded T-cell engager from China's Abogen Biosciences, in a deal valued at up to $7.8 billion with a $575 million upfront payment. The therapy is designed to produce a CD3xCD19 T-cell engager inside patients to target cancer and autoimmune diseases. Novartis also holds options for additional programs based on Abogen's RNA platform. The agreement ranks among the largest China-related biopharma transactions reported in early October 2026.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (41)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Novartis secured exclusive worldwide rights to ABO2203 from Abogen Biosciences.
  • ✓ The deal is valued at up to $7.8 billion with a $575 million upfront payment.
  • ✓ ABO2203 is an experimental mRNA-encoded T-cell engager targeting CD3xCD19.
  • ✓ The therapy aims to treat cancer and autoimmune diseases by producing the engager within the patient.
🛡️ Source Corroboration: 41 independent reporting domains (95% confidence) ⏱ Read time: ~2 min

What changed

Initial report of the licensing agreement, financial terms, and mechanism of ABO2203.

Live updates

  1. Novartis licenses Abogen mRNA T-cell engager in up to $7.8B deal

    Novartis has secured exclusive worldwide rights to ABO2203, an experimental mRNA-encoded T-cell engager from China's Abogen Biosciences, in a deal valued at up to $7.8 billion with a $575 million upfront payment. The therapy is designed to produce a CD3xCD19 T-cell engager inside patients to target cancer and autoimmune diseases. Novartis also holds options for additional programs based on Abogen's RNA platform. The agreement ranks among the largest China-related biopharma transactions reported in early October 2026.

    Why it matters

    Novartis, a Swiss pharmaceutical giant formed from the 1996 merger of Ciba-Geigy and Sandoz, is expanding its RNA-based therapeutic pipeline through this partnership. The deal signals growing Western pharma confidence in Chinese mRNA innovation and positions Novartis to compete in the next generation of in vivo T-cell engagers.

    What is confirmed

    • Novartis secured exclusive worldwide rights to ABO2203 from Abogen Biosciences.
    • The deal is valued at up to $7.8 billion with a $575 million upfront payment.
    • ABO2203 is an experimental mRNA-encoded T-cell engager targeting CD3xCD19.
    • The therapy aims to treat cancer and autoimmune diseases by producing the engager within the patient.
    • Novartis holds options for additional programs based on the Abogen RNA platform.

    What to watch next

    • Clinical trial initiation timeline for ABO2203
    • Exercise of options for additional Abogen pipeline programs
    • Regulatory feedback on in vivo mRNA-encoded T-cell engager approach
    Sources used for this update (8)
    1. en.wikipedia.org — Novartis - Wikipedia
    2. www.novartis.com — Novartis Pharmaceuticals United States of America
    3. novartis.wd3.myworkdayjobs.com — Search for Jobs
    4. finance.yahoo.com — Novartis AG (NVS) Stock Price, News, Quote & History - Yahoo...
    5. pap.novartis.com — Novartis Patient Assistance Foundation
    6. www.decibio.com — Healthcare Investment | October Roundup 2026 - decibio.com
    7. de.wikipedia.org — Novartis – Wikipedia
    8. portals.novartis.com — Novartis Patient Support
    confidence 95%
  2. Novartis acquires rights to Abogen mRNA therapy in $7.8 billion deal

    Novartis secured exclusive worldwide rights to ABO2203, an experimental mRNA-encoded T-cell engager from Abogen Biosciences. The deal is valued at up to $7.8 billion and includes a $575 million upfront payment. The therapy targets cancer and autoimmune diseases by producing a CD3xCD19 T-cell engager within the patient. Novartis also holds options for additional programs based on the Abogen RNA platform. This agreement ranks as one of the largest China-related biopharmaceutical transactions reported in early October 2026.

    Why it matters

    The deal reflects a broader industry trend where major pharmaceutical firms invest in RNA therapeutics and T-cell engagers to expand oncology and autoimmune pipelines. It highlights the ongoing strategic importance of Chinese biotech platforms for scalable innovation.

    What is confirmed

    • Novartis paid $575 million upfront for exclusive worldwide rights to ABO2203.
    • The total value of the agreement with Abogen Biosciences reaches up to $7.8 billion.
    • ABO2203 is an mRNA-encoded T-cell engager designed for cancer and autoimmune diseases.
    • The therapy generates a CD3xCD19 T-cell engager inside the body.
    • Novartis secured options for further programs derived from the Abogen RNA platform.

    What to watch next

    • Clinical trial results for ABO2203 in cancer or autoimmune cohorts
    • Novartis decision to exercise options for additional Abogen RNA platform programs
    Sources used for this update (2)
    1. www.biobucks.co — Biotech BD&L Tracker 2026: 156 Licensing & Partnering Deals
    2. www.dimabio.com — October 2026 Global Biopharma Deal Roundup: Billion-Dollar ...
    confidence 100%
  3. Novartis Licenses Abogen mRNA Drug in Multibillion-Dollar Deal

    Novartis secured exclusive worldwide rights to ABO2203 from Abogen Biosciences in an agreement valued at up to $7.8 billion. The transaction features an upfront payment of $575 million for the experimental mRNA-encoded T-cell engager. This therapy treats cancer and autoimmune diseases by generating a CD3xCD19 T-cell engager inside the body. Novartis also secured options for further programs derived from the Abogen RNA platform. This transaction stands as one of the largest China-related biopharmaceutical deals reported for early October 2026.

    Why it matters

    The biotechnology sector continues to watch mRNA applications expand beyond vaccines into complex disease areas like oncology and immunology. Developing scalable and reproducible manufacturing processes remains a key challenge for these advanced therapeutics. This partnership highlights the growing integration of Chinese biotech innovation into global pharmaceutical pipelines.

    What is confirmed

    • Novartis acquired exclusive worldwide rights to the experimental mRNA-encoded T-cell engager ABO2203 from Abogen Biosciences.
    • The agreement carries a total potential value of up to $7.8 billion and includes an upfront payment of $575 million.
    • The therapy functions by generating a CD3xCD19 T-cell engager inside the body to treat cancer and autoimmune diseases.
    • Novartis obtained options for additional programs from Abogen's RNA platform.

    What to watch next

    • Progression of ABO2203 into clinical trials and regulatory filings
    • Exercise of options for additional programs from Abogen's RNA platform
    Sources used for this update (2)
    1. theedgemalaysia.com — Bloomberg] - The Edge Malaysia
    2. www.yeasenbio.com — From Molecule to Platform: What the Abogen–Novartis Deal ...
    confidence 100%
  4. Novartis Licenses Abogen mRNA Candidate in $7.8 Billion Deal

    Novartis has acquired exclusive worldwide rights to ABO2203, an experimental mRNA-encoded T-cell engager from China-based Abogen Biosciences. The agreement is valued at up to $7.8 billion and includes an upfront payment of $575 million. The therapy generates a CD3xCD19 T-cell engager within the body to treat cancer and autoimmune diseases. Novartis also holds options for additional programs from Abogen's RNA platform. This deal marks one of the largest China-related biopharmaceutical transactions reported for early October 2026.

    Why it matters

    Novartis is seeking to recover after trial failures erased $30 billion in value. Abogen aims to demonstrate that its mRNA technology is effective for therapeutic uses beyond COVID-19 vaccines.

    What is confirmed

    • Novartis secured exclusive worldwide rights to ABO2203 from Abogen Biosciences.
    • The deal is valued at up to $7.8 billion.
    • Novartis paid $575 million upfront.
    • ABO2203 is an mRNA-encoded T-cell engager targeting CD3xCD19 for cancer and autoimmune diseases.
    • The agreement includes options for other programs from Abogen's RNA platform.

    What to watch next

    • Clinical trial results for ABO2203
    • Novartis decision on exercising options for additional RNA programs
    Sources used for this update (3)
    1. www.biospace.com — Novartis - BioSpace
    2. biotochina.org — Vol. 102, 2026 YAFO Weekly Global Wrap-up Report 雅法全球生物医药...
    3. thenationtimes.com — Novartis to License Drug From China’s Abogen in Up to $7.8 ...
    confidence 95%
  5. Novartis pays $575 million upfront in $7.8 billion Abogen mRNA deal

    Novartis has secured exclusive worldwide rights to ABO2203, an experimental mRNA-encoded T-cell engager from China's Abogen Biosciences, in a deal valued up to $7.8 billion. The agreement includes a $575 million upfront payment and options for additional programs from Abogen's RNA platform. The therapy targets autoimmune diseases and cancer by generating a CD3xCD19 T-cell engager inside the body. This transaction follows a period of trial failures that removed $30 billion in value from Novartis and comes as Abogen seeks to prove its mRNA technology has therapeutic utility beyond COVID-19 vaccines.

    Why it matters

    Abogen is a Suzhou-based biotech company founded in 2019. The deal signals continued Western investment in Chinese biotech despite broader geopolitical tensions. The specific mRNA design aims to reduce the risk of dangerous cytokine release during treatment.

    What is confirmed

    • Novartis paid $575 million upfront to license Abogen's mRNA therapy ABO2203.
    • The total value of the licensing deal is up to $7.8 billion.
    • ABO2203 is an in vivo mRNA-encoded T-cell engager designed to treat autoimmune diseases.
    • The agreement includes options for future therapies from Abogen's RNA platform.
    • Abogen Biosciences is a biotech company based in Suzhou, China, founded in 2019.

    Still unconfirmed

    • The United States is considering allowing US-China pharmaceutical deals to continue while remaining cautious in other sectors.
    • Trial failures recently erased $30 billion in value from Novartis.

    What to watch next

    • Clinical trial results for ABO2203 in autoimmune or cancer patients
    • Exercise of options for additional programs from Abogen's RNA platform
    Sources used for this update (13)
    1. www.marketbeat.com — NVS News Today | Why did Novartis stock go down today?
    2. www.biospace.com — How Abogen went from COVID hype to a $7.8B Novartis deal
    3. for.you.com — Novartis Abogen Deal: $575M Upfront Bet on mRNA Autoimmune Drug
    4. chinaarticles.substack.com — The Cake that Gerhard Baked - by Matt Turpin
    5. patientdaily.com — Novartis signs $7.8 billion licensing deal with Abogen ...
    6. www.pharmawire.org — Novartis bets on China's Abogen in $7.8bn mRNA licensing deal
    7. www.iam-media.com — Novartis inks $7.8 billion mRNA deal with Chinese company Abogen
    8. www.vcbeathealth.com — Multiple Chinese Pharma License-out Deals Closed in Early ...
    9. www.biospace.com — China - BioSpace
    10. www.thepharmaletter.com — Abogen Biosciences | The Pharma Letter | The Pharmaletter
    11. biotechmorning.com — Novartis Just Bet $7.8 Billion That Your Body Can Build Its ...
    12. public.com — Novartis (NVS) Latest News & Stock Updates - Page 1
    confidence 95%
  6. Novartis Licenses Abogen mRNA Drug in $7.8B China Deal

    Novartis has agreed to a licensing transaction valued at up to $7.8 billion with Chinese biotechnology company Abogen Biosciences to secure exclusive worldwide rights to an experimental messenger RNA asset. The therapy, identified as ABO2203, is an in vivo mRNA-encoded T-cell engager designed to generate a CD3xCD19 T-cell engager inside the human body for the treatment of autoimmune diseases. According to Abogen, the design aims to potentially lower the risk of dangerous cytokine release. The agreement includes options covering future therapies as major Western drugmakers continue investing in early-stage Chinese biotechnology innovation.

    Why it matters

    Western pharmaceutical companies are increasingly turning to Chinese biotech firms for early-stage pipeline assets, following similar licensing agreements executed by Novo Nordisk, GSK, and AstraZeneca. The transaction expands Novartis beyond traditional vaccine applications of messenger RNA technology into complex autoimmune treatments. BofA Global Research forecasts that Novartis will report higher year-over-year sales for the third quarter, supported by strong key growth drivers.

    What is confirmed

    • Novartis signed a licensing agreement valued at up to $7.8 billion with Chinese biotechnology company Abogen Biosciences.
    • The transaction grants Novartis exclusive worldwide rights to the experimental mRNA asset ABO2203.
    • The therapeutic asset is an in vivo mRNA-encoded T-cell engager designed to produce a CD3xCD19 T-cell engager inside the human body.
    • Abogen stated the design could potentially lower the risk of dangerous cytokine release.

    Still unconfirmed

    • BofA Global Research forecasts higher year-over-year sales for Novartis in the third quarter.

    What to watch next

    • Progression of the ABO2203 clinical candidate through regulatory and development phases.
    • Novartis third-quarter financial results reporting and commentary on sales growth drivers.
    Sources used for this update (7)
    1. www.marketscreener.com — Novo Nordisk Provides Update on Denecimig Biologics License Application in the US | MarketScreener
    2. www.biospectrumasia.com — Novartis signs licensing deal worth $7.2 B with China's ...
    3. capitaldigest.com — Novartis $7.8B China Biotech Deal Signals Big Pharma Shift
    4. biotechmorning.com — Novartis Just Bet $7.8 Billion That mRNA Can Do Way More Than ...
    5. www.marketscreener.com — BofA Expects Higher Q3 Sales from Novartis Amid Strong Key Growth Drivers | MarketScreener
    6. www.europesays.com — Novartis signs $7.8B mRNA deal with Chinese biotech
    7. globalpolitics.info — Novartis Partners with Abogen on $7.8 Billion Biotech Deal
    confidence 100%
  7. Novartis Strikes $7.8B mRNA Deal with Abogen

    Novartis agreed to license an experimental messenger RNA-based autoimmune therapy from Chinese biotechnology company Abogen Biosciences in an agreement valued at up to $7.8 billion. The transaction includes options over future therapies as Novartis taps into early-stage Chinese biotech innovation. The therapeutic asset is an in vivo mRNA-encoded T-cell engager designed to produce a CD3xCD19 T-cell engager inside the human body, which Abogen stated could potentially lower the risk of dangerous cytokine release.

    Why it matters

    Western pharmaceutical firms increasingly source early-stage medical innovations from Chinese biotech startups to bolster pipelines. This transaction represents a significant financial commitment by Novartis toward messenger RNA applications outside traditional vaccine fields. Details regarding the clinical timeline for the candidate remain unreleased.

    What is confirmed

    • Novartis struck a deal valued at up to $7.8 billion to license a messenger RNA drug candidate from Abogen Biosciences.
    • The agreement includes options over future therapies from Abogen Biosciences.
    • The licensed asset is an in vivo mRNA-encoded T-cell engager designed to produce a CD3xCD19 T-cell engager inside the human body.
    • Abogen stated that this method could potentially lower the risk of dangerous cytokine release.

    What to watch next

    • Disclosures regarding upfront payments and financial milestones associated with the $7.8 billion valuation.
    • Clinical trial timelines for the in vivo mRNA-encoded T-cell engager candidate.
    Sources used for this update (3)
    1. www.gdnonline.com — Health: Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
    2. www.marketscreener.com — Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal -- Update | MarketScreener
    3. www.marketscreener.com — Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal | MarketScreener
    confidence 100%
  8. Novartis Licenses Abogen mRNA Drug in $7.8B Deal

    Novartis has agreed to license an experimental messenger RNA-based autoimmune therapy from Chinese biotechnology company Abogen Biosciences in an agreement valued at up to $7.8 billion. The therapeutic asset is an in vivo mRNA-encoded T-cell engager designed to produce a CD3xCD19 T-cell engager inside the human body. Abogen stated that this method could potentially lower the risk of dangerous cytokine release. The transaction expands a growing trend of Western pharmaceutical firms sourcing early-stage innovation from Chinese biotech startups.

    Why it matters

    Large pharmaceutical corporations are increasingly pursuing licensing agreements with Chinese biotechnology developers as an approaching patent cliff threatens existing revenue streams. This transaction forms part of a broader wave of industry spending on experimental treatments, which also includes deals involving companies such as Sanofi and Novo Nordisk. Abogen confirmed the financial terms and scope of the agreement on Friday.

    What is confirmed

    • Novartis agreed to license an mRNA-based autoimmune therapy from China's Abogen Biosciences in a deal worth as much as $7.8 billion.
    • The therapy is an in vivo mRNA-encoded T-cell engager designed to produce a CD3xCD19 T-cell engager inside the body.
    • Abogen Biosciences stated that the in vivo approach could reduce the likelihood of dangerous cytokine release.

    What to watch next

    • Further clinical development milestones and regulatory filings for the Abogen mRNA therapy
    • Additional financial details regarding upfront and milestone payments in the Novartis and Abogen partnership
    Sources used for this update (14)
    1. www.novartis.com — Novartis
    2. WSJ — Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
    3. Reuters — Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
    4. CNBC — Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
    5. Bloomberg.com — Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion
    6. fiercebiotech.com — Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
    7. axios.com — Novartis signs $7.8 billion drug deal with Chinese startup
    8. www.cnbc.com — Novartis signs $7.8 billion Abogen biotech licensing deal - CNBC
    9. biopharmaapac.com — Novartis Signs $7.8B RNA Therapeutics Deal With Abogen Biosciences
    10. medicaldialogues.in — Novartis Signs Licensing Deal Worth Up to $7.8 Billion With Abogen for mRNA Therapies - Medical Dialogues
    11. finance.yahoo.com — Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
    12. theedgemalaysia.com — Novartis inks Chinese mRNA-therapy deal for up to US$7.8 bil - The Edge Malaysia ,Make Better Decisions
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community